For the quarter ending 2026-03-31, AQST had -$10,435K decrease in cash & cash equivalents over the period. -$14,858K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Gain on contract termination | - | 0 | 0 | 0 |
| Net loss | -8,057 | -31,860 | -15,446 | -36,478 |
| Depreciation, amortization, and impairment | 113 | 130 | 139 | 279 |
| Share-based compensation | 2,318 | 1,376 | 2,777 | 3,471 |
| Issuance of warrants | 916 | - | - | - |
| Amortization of debt issuance costs and discounts | 2,286 | 2,749 | 2,748 | 5,498 |
| Other, net | -6 | -1 | -11 | 11 |
| Trade and other receivables, net | -10,896 | 5,959 | -63 | 4,476 |
| Inventories | 1,896 | -1,714 | -241 | 2,081 |
| Prepaid expenses and other assets | 340 | 685 | 1,721 | -3,104 |
| Accounts payable | -17,973 | 19,247 | -1,306 | 1,582 |
| Accrued expenses and other liabilities | -2,803 | 5,090 | 118 | -2,176 |
| Deferred revenue | -272 | -272 | -273 | -26 |
| Net cash used for operating activities | -14,806 | -8,469 | -12,649 | -31,314 |
| Capital expenditures | 52 | 85 | 235 | 242 |
| Net cash used for investing activities | -52 | -85 | -235 | -242 |
| Proceeds from common stock issued under public equity offering-atm, net | 4,759 | 21,194 | - | - |
| Proceeds from common stock issued under public equity offering-At The Market Offering | - | - | -9 | 21,236 |
| Proceeds from common stock issued under public equity offering, net | - | 79,460 | - | - |
| Proceeds from common stock issued under public equity offering-Public Equity Offering | - | - | 79,728 | 0 |
| Proceeds from exercise of warrants, net | - | 0 | 1,430 | - |
| Proceeds from shares issued under employee stock purchase plan | - | 60 | 0 | 50 |
| Proceeds from exercise of stock options, net | 1 | 924 | 339 | 7 |
| Repayment of debt principal including lease liabilities | 8 | 5 | 7 | 14 |
| Payments for royalty obligations | 0 | 0 | 0 | 11 |
| Payments for taxes on share-based compensation, net | 329 | 18 | 70 | 722 |
| Net cash provided by financing activities | 4,423 | 660 | 81,411 | 20,546 |
| Net increase in cash and cash equivalents | -10,435 | -7,894 | 68,527 | -11,010 |
| Cash and cash equivalents at beginning of period | 121,169 | 129,063 | 71,546 | - |
| Cash and cash equivalents at end of period | 110,734 | 121,169 | 129,063 | - |
Aquestive Therapeutics, Inc. (AQST)
Aquestive Therapeutics, Inc. (AQST)